Delineating the Mechanisms Mediating Piezo-1- Induced Liver Regeneration
(A) Schematic diagram of the rat PVL model. (B) Changes in the ratio of liver weight to body weight in each lobe after 70% PVL in rats (the changes of each liver lobe were compared with 0 h). (C) Immunofluorescence staining analysis of Ki67 (in PV-CV) in
(A) WB revealed that EGFR was activated by recombinant proteins of AREG (50 ng/mL) and EREG (20 ng/mL) in LO2 cells. (B) The MTT assay at 24 and 48 h suggested that gefitinib could block the proliferation of hepatocytes induced by AREG (50 ng/mL) and EREG
(A, B) The qRT-PCR results showed increased mRNA expression of HBEGF, EREG, and AREG induced by Yoda1 in endothelial cells and was reversed with Piezo1 knockdown in HUVEC cells. (C, D) the ELISA assay results showed that increased secretion of EREG and AR
Theoretical basis for mechanical stimulation-mediated chemical signals-induced liver regeneration
CHINA, March 11, 2025 /EINPresswire.com/ -- Liver regeneration (LR) is a complex biological process involving the proliferation of parenchymal (hepatocytes) and non-parenchymal cells within the liver and is mediated by a complex interplay of inflammatory and growth factors. Hemodynamic changes following liver injury activate mechanosensing structures in vascular endothelial cells (VECs) to produce large amounts of cytokines, which play a crucial role in LR. Piezo-1 is a critical mechanosensory ion channel that can detect and convert mechanical forces into chemical signals to trigger downstream biological effects; however, its role in VECs, especially in regulating LR, remains unclear.
In this study, published in the Genes and Diseases journal, researchers from Jilin University, Chinese Academy of Medical Sciences, and Tsinghua University show that early changes in hepatic portal hemodynamics activate Piezo1 in VECs to promote hepatocyte proliferation during the LR process induced by portal vein ligation (PVL) in rats.
The authors showed that at 24–48 h post-portal vein ligation, hepatocyte proliferation, indicated by Ki67-positive cells, was mainly seen distributed in zone 1 and zone 2 of liver lobules, while only a few Ki67-positive hepatocytes were observed in zone 3. Subsequently, hemodynamic changes post-PVL enhanced the expression of Piezo-1 in liver VECs and sinusoidal endothelial cells. Additionally, the authors showed that Yoda-1 (a specific agonist of Piezo-1)-mediated Piezo-1 activation in VECs was associated with proliferation and EMT of the hepatocytes.
The study further showed that Yoda-1-mediated Piezo-1 activation was associated with the upregulation of ERBB and MAPK signaling pathways, along with a concomitant increase in the expression of heparin-binding epidermal growth factor (HBEGF), epiregulin (EREG), and amphiregulin (AREG)—proteins that promote hepatocyte proliferation and partial EMT via the PKC/ERK1/2 signaling pathways. It was observed that Yoda1 could promote the proliferation and partial EMT of hepatocytes through the EGFR signaling pathway. Further investigation revealed that AREG and EREG enhanced the phosphorylation of EGFR and promoted hepatocyte proliferation primarily via EGFR activation, while also inducing a partial EMT-like response through ERK1/2 activation.
In conclusion, this study demonstrates that Piezo1 activation in VECs leads to the up-regulation of HBEGF, EREG, and AREG gene expression in the ERBB signaling pathway through the PKCα-ERK1/2 axis, which in turn activates EGFR in hepatocytes, promoting cell proliferation and inducing a partial EMT-like response. The findings of this study provide mechanistic insights into how chemical signals mediated by mechanical stimulation regulate liver regeneration.
Reference
Title of the original paper - EGFR-mediated crosstalk between vascular endothelial cells and hepatocytes promotes Piezo1-dependent liver regeneration
Journal - Genes & Diseases
Genes & Diseases is a journal for molecular and translational medicine. The journal primarily focuses on publishing investigations on the molecular bases and experimental therapeutics of human diseases. Publication formats include full length research article, review article, short communication, correspondence, perspectives, commentary, views on news, and research watch.
DOI - https://doi.org/10.1016/j.gendis.2024.101321
Funding Information:
National Key Research and Development Program of China (No. 2022YFA1103400)
The CAMS Innovation Fund for Medical Sciences (No. 2019-I2M-5–056)
The National Natural Science Foundation of China (No. 81930119, 92168207, 32371477, 82090051)
The Precision Medicine Research Program of Tsinghua University (No. 10001020612)
The National High Level Hospital Clinical Research Funding (China) (No. 2022-NHLHCRF-LX-03-0102
# # # # # #
Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.
Scopus CiteScore: 7.3 | Impact Factor: 6.9
# # # # # #
More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/
All issues and articles in press are available online in ScienceDirect (https://www.sciencedirect.com/journal/genes-and-diseases).
Submissions to Genes & Disease may be made using Editorial Manager (https://www.editorialmanager.com/gendis/default.aspx ).
Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R
Contact Us: editor@genesndiseases.com
X (formerly Twitter): @GenesNDiseases (https://x.com/GenesNDiseases)
Genes & Diseases Editorial Office
Genes & Diseases
+86 23 6571 4691
email us here
Visit us on social media:
Facebook
X
LinkedIn
Instagram
YouTube
Other
Distribution channels: Education, Healthcare & Pharmaceuticals Industry, Science
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Submit your press release